Chelsea Counsel Co. Trims Position in Johnson & Johnson (NYSE:JNJ)

Chelsea Counsel Co. lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 7.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 21,880 shares of the company's stock after selling 1,744 shares during the quarter. Johnson & Johnson makes up 1.6% of Chelsea Counsel Co.'s portfolio, making the stock its 16th biggest position. Chelsea Counsel Co.'s holdings in Johnson & Johnson were worth $3,164,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Carolinas Wealth Consulting LLC grew its stake in shares of Johnson & Johnson by 122.5% during the 4th quarter. Carolinas Wealth Consulting LLC now owns 5,083 shares of the company's stock worth $735,000 after purchasing an additional 2,799 shares during the period. Yoffe Investment Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth about $542,000. LifeWealth Investments LLC purchased a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $226,000. Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $50,000. Finally, LM Advisors LLC increased its position in shares of Johnson & Johnson by 54.3% during the fourth quarter. LM Advisors LLC now owns 12,245 shares of the company's stock worth $1,771,000 after purchasing an additional 4,311 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on JNJ shares. Leerink Partners cut shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Raymond James decreased their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Trading Up 0.3%

NYSE JNJ traded up $0.52 on Thursday, reaching $152.95. The stock had a trading volume of 2,353,932 shares, compared to its average volume of 7,931,169. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The stock has a fifty day moving average price of $154.63 and a two-hundred day moving average price of $153.64. The firm has a market capitalization of $368.02 billion, a price-to-earnings ratio of 23.00, a P/E/G ratio of 2.56 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.40%. The ex-dividend date of this dividend is Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.